These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 3893504)

  • 1. The use of sustained-release theophylline ('Theo-dur') for the treatment of chronic reversible obstructive lung disease in hospital practice.
    Riddington CJ; Shipman AJ
    Br J Clin Pract; 1985 Apr; 39(4):148-53. PubMed ID: 3893504
    [No Abstract]   [Full Text] [Related]  

  • 2. A comparative trial of ipratropium bromide (Atrovent), controlled release theophylline (Phyllocontin), and a combination of these in patients with reversible airflow obstruction.
    Sahay JN; Chatterjee SS; Summerfield PJ
    Br J Clin Pract; 1986 May; 40(5):198-202. PubMed ID: 2944533
    [No Abstract]   [Full Text] [Related]  

  • 3. [Obstructive airway diseases. Basic therapy with pure theophylline in retard form].
    Pollert I
    Fortschr Med; 1982 Mar; 100(12):547-50. PubMed ID: 7042500
    [No Abstract]   [Full Text] [Related]  

  • 4. Maintenance of bronchodilation in chronic reversible airways obstruction. Comparison between choline theophyllinate and salbutamol.
    Tanser AR
    Practitioner; 1982 Mar; 226(1365):569-71. PubMed ID: 7045848
    [No Abstract]   [Full Text] [Related]  

  • 5. [Long-term therapy with a retard theophylline preparation].
    Keller A; Bömches B; Kandt D
    Fortschr Med; 1995 May; 113(13):197-202. PubMed ID: 7782018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of once-daily Uniphyl tablets compared with twice-daily Theo-Dur tablets in elderly patients with chronic airflow obstruction.
    Rivington RN; Calcutt L; Hodder RV; Stewart JH; Aitken TL
    Am J Med; 1988 Jul; 85(1B):48-53. PubMed ID: 3041826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term therapy with sustained-release theophylline.
    Myhre KI; Arnulf V; Walstad RA
    Pharmatherapeutica; 1985; 4(2):92-7. PubMed ID: 3903782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum theophylline concentrations and pulmonary function tests after administration of two sustained-release formulations containing theophylline in patients affected by chronic obstructive lung disease.
    Fontana G; Cresci F; Lo Sapio P; Panuccio P
    Int J Clin Pharmacol Res; 1987; 7(5):351-6. PubMed ID: 3667008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical experience with theophylline in slow-release form (Theo-dur)].
    Jørstad SO; Omenaas E
    Tidsskr Nor Laegeforen; 1982 May; 102(13):747-9. PubMed ID: 6760450
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical effectiveness of delayed-action theophylline preparations].
    Tsoĭ AN; Gavrilenko LN; Bogovskiĭ BP; Semenova LG; Iuldasheva LI
    Klin Med (Mosk); 1990 Sep; 68(9):72-5. PubMed ID: 2290338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical functional study of a new delayed-action preparation of "once a day" anhydrous theophylline in patients with chronic obstructive bronchopneumopathy].
    Gatto PG; Bruzzoni A; Valenti V
    Clin Ter; 1989 Jul; 130(1):45-9. PubMed ID: 2529079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prescription of Theostat 300 as a single evening dose].
    Germouty J; Bida C; Moreau L
    Rev Pneumol Clin; 1987; 43(5):262-5. PubMed ID: 3324266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapy of obstructive respiratory tract diseases. Study of afonilum retard in 3,512 patients].
    Eichhorn J; Perré R
    Med Welt; 1982 Dec; 33(50):1834-7. PubMed ID: 6762480
    [No Abstract]   [Full Text] [Related]  

  • 14. [Therapy of obstructive respiratory tract diseases with pure theophylline retard].
    Arens PJ
    Med Klin Prax; 1982 Aug; 77(18):48-53, 67. PubMed ID: 6752679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of standard- and sustained-release theophylline tablets in patients with chronic obstructive pulmonary disease.
    Dasta J; Mirtallo JM; Altman M
    Am J Hosp Pharm; 1979 May; 36(5):613-7. PubMed ID: 453214
    [No Abstract]   [Full Text] [Related]  

  • 16. [Theophylline in the therapy of non reversible airway obstruction].
    Drigo R; Bevilacqua M; Franco R
    G Clin Med; 1987 Jan; 68(1):39-45. PubMed ID: 3301490
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical results obtained from a new controlled release theophylline preparation.
    Nolte D
    Br J Clin Pract Suppl; 1984; 32():14-7. PubMed ID: 6432017
    [No Abstract]   [Full Text] [Related]  

  • 18. [Use of a new delayed-release anhydrous theophylline by single daily administration in the treatment of reversible bronchial obstruction. Comparison with a delayed-release preparation administered twice daily].
    Baronti A; Verdiani P; Di Carlo S
    Clin Ter; 1987 Sep; 122(6):437-40. PubMed ID: 2972456
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of two sustained-release theophylline preparations in adult patients with obstructive airways disease.
    Harkaway PS; Conlon PF; Hirsh JD; Allen WT
    J Clin Pharmacol; 1985 Sep; 25(6):444-7. PubMed ID: 4056079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma theophylline concentrations in patients with chronic obstructive airways disease after administration of a new sustained release theophylline formulation.
    Taylor DR; Kinney CD; McDevitt DG
    Br J Clin Pharmacol; 1982 Apr; 13(4):569-71. PubMed ID: 7066172
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.